Investigating nitroglycerin and misoprostol on cervical ripening

Comparative effect of sublingual Nitroglycerin and sublingual Misoprostol on Cervical ripening before Hysteroscopy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191123045476N4

Enrollment

Registered

2023-09-01

Start date

2023-06-20

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hysteroscopy candidate patients.

Interventions

Intervention 1: Intervention group 1: 42 patients under general anesthesia receive sublingual nitroglycerin (Zahrawi Company, Iran) at a dosage of 0.4 mg 30 minutes before the operation. Intervention

Eligibility

Sex/Gender

Female

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: age between 18-50 years (reproductive age) history of at least one Normal Vaginal Delivery being a candidate for hysteroscopy

Exclusion criteria

Exclusion criteria: history of drug allergy cardiovascular diseases

Design outcomes

Primary

Measure	Time frame
Cervical dilatation. Timepoint: Immediately after taking the drug during surgery. Method of measurement: In the operating room, the opening of the cervix is measured in millimeters using sized dilators.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSamaneh Rokhgireh

Iran University of Medical Sciences

Rokhgireh.s@iums.ac.ir+98 21 6650 9283

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 5, 2026